To validate the clinical importance of TROP2 in HNSCC, the gene expression was evaluated in 42 HNSCC patients, including 24 laryngeal and 18 hypopharyngeal carcinomas. Here, TACSTD2 is linked to head and neck squamous cell carcinoma.